Guess which ASX All Ords share just rocketed 40%

Shares in investigative analytics software provider are moving like a bat out of hell.

| More on:
Man pointing at a blue rising share price graph.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Shares in this investigative analytics company are up 40% to $1.15 today
  • The sensational reception comes amid management's rosy expectations for the company's FY24 full-year results
  • Statutory EBITDA is forecast to increase between 164% to 189% compared to the prior year

One ASX All Ords share is putting the rest of the S&P/ASX All Ordinaries Index (ASX: XAO) to shame today.

Shares in investigative analytics software provider Nuix Ltd (ASX: NXL) are moving like a bat out of hell following the release of the company's FY23 preliminary results update. As we head into the afternoon, the share price is currently trading at $1.15, up 40.2% from yesterday.

Let's take a closer look at what is getting investors excited.

Promising signs for growth

Earlier this morning, Nuix shares were up as much as 51.2%, marking the biggest jump in share price in more than five months. While the enthusiasm has calmed as the day has gone on, the unaudited financials for FY2023 are no less delighting shareholders.

Following a succession of disappointing results since its listing in 2020, the software provider is giving its first glimpse of a change in trajectory.

In its update, the ASX All Ords constituent revealed it expects substantial increases across several metrics for the full year, including:

  • Annualised contract value (ACV) between $184 million and $186 million — up 14% to 15%
  • Statutory revenue between $181 million and $183 million — up 19% to 20%
  • Underlying EBITDA between $44 million to $47 million — up 51% to 61%
  • Statutory EBITDA between $32 million to $35 million — up 164% to 189%

It should be noted that the underlying figure excludes non-operational legal costs and costs related to its acquisition of Topos.

According to the release, the strong performance was aided by several key contracts being executed in June. Additionally, currency fluctuations assisted Nuix's ACV and statutory revenue by 3% to 4%.

Shareholders might also be looking favourably at the reduction in legal costs year-on-year. While these costs grew from the first half to the second half — as previously expected — the amount fell from $14 million to $8 million in FY22 versus FY23.

What's ahead for this ASX All Ords share?

It's been a wild ride for Nuix shareholders in 2023. In the first month and a half of the year, the company's shares skyrocketed 138%, followed by a bumpy decline (charted below) — until today.

Today's rally takes the Nuix share price to a year-to-date gain of 75%. However, the figures presented today are preliminary. The final full-year numbers will be shared with investors on 18 August.

Those that have stuck with this ASX All Ords share should then get a glimpse at where management's expectations lay for FY24.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Share Gainers

3 ASX 200 stocks storming higher in this week's sinking market

Investors have sent these three ASX 200 stocks soaring this week. But why?

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Gainers

Why 4DMedical, Develop Global, EOS, and Maas shares are racing higher today

These shares are ending the week on a high. But why?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 657% in a year, 4DMedcial shares rocketing another 20% today on big US news

ASX investors can’t get enough of 4DMedical shares today. Let’s see why.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 broke its losing streak to inch higher today.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Consumer Staples & Discretionary Shares

Bapcor shares soar 12% on the appointment of a new CEO

The market’s strong reaction reflects a clear message: investors are ready for a reset.

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Share Gainers

Why Bapcor, IDP Education, Netwealth, and Ora Banda shares are pushing higher today

These shares are catching the eye with solid gains on Thursday. But why are they rising?

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX stock is going parabolic, and I think it's still a buy

4DMedical shares are up nearly 500% in 2025, but improving revenue visibility suggests the growth story may not be over.

Read more »